



DH CIRCULAR No.110/2014

DH 1467/2014

27 March 2014

Attention All: Consultants
Medical Officers
Pharmacists
Pharmacy Technicians
Nurses

Re: Atomoxetine 10mg, 18mg, 25mg, 40mg, and 60mg Capsules

Atomoxetine 10mg, 18mg, 25mg, 40mg, and 60mg hard capsules have been recommended by the Government Formulary List Advisory Committee for introduction onto the Government Formulary List.

Atomoxetine capsules are protocol-regulated with protocol number 4 (attached) and can be prescribed by Consultant Paediatricians (Community Paediatrics), Consultant Paediatricians (Paediatric Neurology and Neurodisability) and Consultant Psychiatrists.

Atomoxetine is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Atomoxetine 10mg, 18mg, 25mg, 40mg, and 60mg hard capsules have been procured and are now available for use as per protocol.

For your attention please

Dr. Neville Calleja
A/Chief Medical Officer

Atomoxetine 10mg, 18mg, 25mg, 40mg and 60mg Capsules

Prescriber Criteria: Consultant Paediatrician (Community Paediatrics)
Consultant Paediatrician (Paediatric Neurology and Neurodisability)
Consultant Psychiatrist

Out-patient and In-patient use:

1. Chronic Psychiatric Disorders Starting in Childhood

Reserved for patients with ADHD:

- in whom methylphenidate is ineffective at the maximum tolerated dose or
- who are intolerant to low or moderate doses of methylphenidate or
- when stimulant medication is contraindicated

Duration of Approval:

1 year